September 7th, 2025 1:30 pm ET
A Tiny Company Taking Aim at a Massive Problem
There’s a shift stirring in small-cap biotech—and it’s not just in the laboratories. Medicus Pharma has quietly assembled a platform packed with near-term catalysts, novel technology, and multi-billion-dollar markets on both oncology and urology fronts.
If you’re scanning for under-the-radar plays with upside potential, this is one ticker worth watching closely.
1. SkinJect: The Patch Poised to Replace the Scalpel
Imagine a patch that can deliver chemo directly through the skin—pain-free, scar-free, outpatient biology.
That’s SkinJect, a dissolvable microneedle patch delivering doxorubicin straight into basal cell carcinoma (BCC) tumors. Here’s the update:
- A Phase 2 trial (SKNJCT-003) has reached 75% enrollment (90 patients across 9 U.S. sites) and shows over 60% clinical clearance in interim results.
- Clinical trial expanded to Europe and a parallel Phase 2 — SKNJCT-004 — is now underway in the UAE, with Study May Proceed approval.
- SkinJect’s safety profile is strong: Phase 1 had no dose-limiting toxicities, and 100% of participants saw complete responses.
All this builds toward a potential FDA fast-track path, with a Type C meeting request pending. A favorable FDA outcome could prove pivotal.
2. Teverelix Acquisition: A $6 Billion Men’s Health Opportunity
Medicus recently acquired Antev Limited, securing rights to Teverelix, a next-gen GnRH antagonist targeting acute urinary retention (AURr) and high-risk prostate cancer.
- The acquisition concluded in September 2025, with $2.97M cash + 1.6M shares paid, and up to $65M in milestone payments.
- Addressable markets: >$2B for AURr and >$4B for advanced prostate cancer; combined, a $6B opportunity.
- High-caliber leadership onboard: Patrick Mahaffy, former Clovis Oncology chairman, joined Medicus’s board.
Now Medicus isn’t just a cancer patch—it’s a multi-indication player with dual upside.
3. Financial Health: Milestone-Backed Momentum
In biotech lingo, cash is everything—dilution fears kill companies.
- Medicus raised $4.2M (Reg A) and $7M (public offering) in 2025, plus $11.5M from warrant exercises.
- Cash position stands at roughly $9.7M as of Q2.
- Operating expenses are accelerating—$6M in Q2 (R&D: $1.4M, G&A: $4.6M), reflecting execution play rather than overreach.
This isn’t biotech scrambling—this is biotech gearing up.
4. Catalysts to Watch—Make MDCX Your Daily Glimpse
Each data point, each slide—not just info, but potential momentum triggers.
5. Why Investors Should Watch (Without Direct Advice)
- Double catalyst runway: Oncology and urology on track.
- Capital secured: Focus remains on execution, not fundraising.
- Leadership and credibility: Acquired board talent signals intent.
- Scarce float = amplified moves: Good news may spark a strong rally.
While no one can predict the market, watching MDCX is smart positioning—your tap could tap into rare asymmetric upside.
This is the kind of story that builds momentum quietly, then roars when data lands.
Medicus Pharma isn’t just another biotech. It’s rewriting the narrative: tiny patches replacing surgery, a multi-billion-dollar urology pipeline in the works, global trials, and money to get there.
Add MDCX to your watchlist. Log in daily. And when a board, pipeline, or trial door opens wide—you want to be in the room, digital or otherwise.
Small Cap Exclusive is owned and operated by King Tide Media, LLC, which is a US based corporation & has been compensated up to $150,000 from Awareness Consulting Network for profiling MDCX with coverage beginning 9/8/25.. We own ZERO shares in MDCX
